A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
Medicalgorithmics Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Medicalgorithmics S.A.
M
M
Medicalgorithmics S.A.
MDG
Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally. It offers PocketECG, an AI-driven online ECG monitoring device for long-term holter, cardiac event, and mobile cardiac telemetry analysis; Kardiobeat.ai, an AI-Driven lightweight wireless holter monitor; DeepRhythm Platform, a hardware-agnostic cloud-based software that leverages cutting-edge AI technology to detect, classify, analyze, and report ECG data; and DeepRhythmAI, a set of algorithms for heart rhythm analysis that integrates into third-party software and devices. The company also provides virtual cardiac stress test (VCAST), an AI-based medical system developed for non-invasive, clinical quantitative, and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. In addition, it operates ECG TechBot, a software using a set of algorithms for automatic analysis and interpretation of the ECG signal based on deep learning methods. In addition, the company engages in the provision of information technology and ECG monitoring services; research and development, including the development of artificial intelligence (AI) algorithms and software for arrhythmia diagnostics, as well as the development and commercialization of AI-based VCAST cardiac imaging technology; and production of electromedical equipment. Medicalgorithmics S.A. company was incorporated in 2005 and is headquartered in Warsaw, Poland.
Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally. It offers PocketECG, an AI-driven online ECG monitoring device for long-term holter, cardiac event, and mobile cardiac telemetry analysis; Kardiobeat.ai, an...
Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally. It offers PocketECG, an AI-driven online ECG monitoring device for long-term holter, cardiac event, and mobile cardiac telemetry analysis; Kardiobeat.ai, an AI-Driven lightweight wireless holter monitor; DeepRhythm Platform, a hardware-agnostic cloud-based software that leverages cutting-edge AI technology to detect, classify, analyze, and report ECG data; and DeepRhythmAI, a set of algorithms for heart rhythm analysis that integrates into third-party software and devices. The company also provides virtual cardiac stress test (VCAST), an AI-based medical system developed for non-invasive, clinical quantitative, and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. In addition, it operates ECG TechBot, a software using a set of algorithms for automatic analysis and interpretation of the ECG signal based on deep learning methods. In addition, the company engages in the provision of information technology and ECG monitoring services; research and development, including the development of artificial intelligence (AI) algorithms and software for arrhythmia diagnostics, as well as the development and commercialization of AI-based VCAST cardiac imaging technology; and production of electromedical equipment. Medicalgorithmics S.A. company was incorporated in 2005 and is headquartered in Warsaw, Poland.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
